Arovella Therapeutics Ltd
ALA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
AMD earnings: Data center demand still looks quite strong to us
AMD has the components to target $100 billion of AI revenue in the next few years.
stocks
PayPal earnings: Growth slows, new CEO appointed
We expect to lower our fair value estimate of PayPal stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,154.90 | 26.00 | -0.28% |
| CAC 40 | 8,222.79 | 39.37 | -0.48% |
| DAX 40 | 24,339.50 | 263.54 | -1.07% |
| Dow JONES (US) | 49,501.30 | 260.31 | 0.53% |
| FTSE 100 | 10,333.59 | 68.75 | -0.66% |
| HKSE | 26,885.24 | 37.92 | 0.14% |
| NASDAQ | 22,904.58 | 350.61 | -1.51% |
| Nikkei 225 | 53,818.04 | 475.32 | -0.88% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,882.72 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,889.20 | 14.80 | -0.17% |
| SSE Composite Index | 4,075.92 | 26.29 | -0.64% |